Page last updated: 2024-09-04

atrasentan and dinoprostone

atrasentan has been researched along with dinoprostone in 1 studies

Compound Research Comparison

Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)	Studies (dinoprostone)	Trials (dinoprostone)	Recent Studies (post-2010) (dinoprostone)
358	41	108	29,105	1,346	6,357

Protein Interaction Comparison

Protein	Taxonomy	dinoprostone (IC50)
Prostaglandin E2 receptor EP1 subtype	Homo sapiens (human)	0.0155
Prostaglandin E2 receptor EP4 subtype	Homo sapiens (human)	0.0031
Prostaglandin E2 receptor EP4 subtype	Rattus norvegicus (Norway rat)	0.0021
Prostaglandin E2 receptor EP3 subtype	Homo sapiens (human)	0.002
Prostaglandin E2 receptor EP2 subtype	Homo sapiens (human)	0.0087
Prostacyclin receptor	Homo sapiens (human)	0.26
Prostaglandin E2 receptor EP2 subtype	Rattus norvegicus (Norway rat)	0.0052

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F	1

Other Studies

1 other study(ies) available for atrasentan and dinoprostone

Article	Year
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14 Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2004

Article

Year

Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14

Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2004